Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles

BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance

Yiping Tu, Steven Renner, Feng-hao Xu, Alex Fleishman, Jeremy Taylor, Jeffrey Weisz, Robert Vescio, Matthew Rettig, James Berenson, Stanislaw Krajewski, John C. Reed and Alan Lichtenstein
Yiping Tu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Renner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feng-hao Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Fleishman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Taylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Weisz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Vescio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Rettig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Berenson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanislaw Krajewski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John C. Reed
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Lichtenstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 1998
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Because murine myeloma plasma cells and normal human lymph node plasma cells express BCL-X, we evaluated BCL-X expression in malignant human plasma cells. BCL-X expression was detected in several human myeloma cell lines, as well as in CD38-sorted bone marrow cells obtained from some patients. Only the antiapoptotic long form of BCL-X (BCL-X-L), was detected. Because BCL-X-L expression can protect tumor cells from apoptotic death induced by chemotherapeutic agents, we tested the clinical relevance of expression in 55 archival bone marrow biopsies. The biopsies were stained by immunohistochemistry, and BCL-X expression was correlated with the subsequent response to treatment. BCL-X expression in malignant plasma cells strongly correlated with decreased response rates in patient groups treated with either melphalan and prednisone or vincristine, Adriamycin, and dexamethasone. Response rates were 83–87% in non-BCL-X-expressing cases and 20–31% in BCL-X-expressing cases. In addition, BCL-X expression was more frequent in specimens taken from patients at relapse (77%), when compared to those at initial diagnosis (29%). Further support for the association of drug resistance with BCL-X-L expression came from studies of the 8226 dox-40 cell line. This line, which expresses p-glycoprotein and serves as a model of multi-drug resistance in multiple myeloma cells, demonstrated an up-regulated expression of BCL-X-L, which was relatively specific, in that BCL-2 or BAX expression was not altered. In addition, dox-40 cells demonstrated a generalized resistance to apoptosis that was induced by several different agents. These results indicate that malignant plasma cells can express BCL-X-L and that such expression may be a marker of chemoresistant disease.

Footnotes

  • ↵1 This work was supported by research funds of the Veterans Affairs, NIH Grant CA-60181, and American Cancer Society Grant DHP32E.

  • ↵2 To whom requests for reprints should be addressed, at Hematology-Oncology, Veterans Affairs West Los Angeles Hospital, W111H, 11301 Wilshire Boulevard, Los Angeles, CA 90073. Phone: (310) 268-3622; Fax: (310) 268-4908.

  • Received July 24, 1997.
  • Accepted November 13, 1997.
  • ©1998 American Association for Cancer Research.
PreviousNext
Back to top
January 1998
Volume 58, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance
Yiping Tu, Steven Renner, Feng-hao Xu, Alex Fleishman, Jeremy Taylor, Jeffrey Weisz, Robert Vescio, Matthew Rettig, James Berenson, Stanislaw Krajewski, John C. Reed and Alan Lichtenstein
Cancer Res January 15 1998 (58) (2) 256-262;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance
Yiping Tu, Steven Renner, Feng-hao Xu, Alex Fleishman, Jeremy Taylor, Jeffrey Weisz, Robert Vescio, Matthew Rettig, James Berenson, Stanislaw Krajewski, John C. Reed and Alan Lichtenstein
Cancer Res January 15 1998 (58) (2) 256-262;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • Explaining Differences in Sensitivity to Killing by Ionizing Radiation between Human Lymphoid Cell Lines
  • p53 Genes Mutated in the DNA Binding Site or at a Specific COOH-terminal Site Exert Divergent Effects on Thyroid Cell Growth and Differentiation
  • Ornithine Decarboxylase Induction in Transformation by H-Ras and RhoA
Show more Regular Articles

Clinical Investigations

  • Human Kallikrein 5
  • Increased Plasma DNA Integrity in Cancer Patients
  • Expansion of Microvascular Bed and Increased Solute Flux in Human Basal Cell Carcinoma in Vivo, Measured by Fluorescein Video Angiography
Show more Clinical Investigations

Articles

  • Human Kallikrein 5
  • Increased Plasma DNA Integrity in Cancer Patients
  • Expansion of Microvascular Bed and Increased Solute Flux in Human Basal Cell Carcinoma in Vivo, Measured by Fluorescein Video Angiography
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement